You are using an outdated browser. Please upgrade your browser to improve your experience.

You are using an outdated browser.

To ensure optimal security, this website will soon be unavailable on this browser. Please upgrade your browser to allow continued use of ACP websites.

Beta-Blocker Therapy (i.e., Bisoprolol, Carvedilol, or Sustained-Release Metoprolol Succinate) for Left Ventricular Systolic Dysfunction (LVSD) Prescribed at Discharge

Proportion of heart failure patients age18 and older with LVSD for whom beta-blocker therapy (i.e., bisoprolol, carvedilol, or sustained-release metoprolol succinate) is prescribed at discharge. For purposes of this measure, LVSD is defined as chart documentation of a left ventricular ejection fraction (LVEF) less than 40% or a narrative description of left ventricular systolic (LVS) function consistent with moderate or severe systolic dysfunction.

Date Reviewed: November 7, 2015

Measure Info

NQF 2438NQF Endorsement Removed
Measure Type: 
Process
Measure Steward: 
The Joint Commission
Clinical Topic Area: 
Heart Failure

Care Setting: 
Inpatient
Data Source: 
Electronic Health Records
Paper Medical Records

ACP supports this measure because it is evidence-based, aligns with current clinical recommendations, and is low burden to physicians, as the data is automatically captured in the electronic medical record.